Search results for "precision"

showing 10 items of 448 documents

Assessing Human Genetic Variations in Glucose Transporter SLC2A10 and Their Role in Altering Structural and Functional Properties

2018

Purpose: Demand is increasing for clinical genomic sequencing to provide diagnoses for patients presenting phenotypes indicative of genetic diseases, but for whom routine genetic testing failed to yield a diagnosis. DNA-based testing using high-throughput technologies often identifies variants with insufficient evidence to determine whether they are disease-causal or benign, leading to categorization as variants of uncertain significance (VUS). Methods: We used molecular modeling and simulation to generate specific hypotheses for the molecular effects of variants in the human glucose transporter, GLUT10 (SLC2A10). Similar to many disease-relevant membrane proteins, no experimentally derived…

0301 basic medicineMolecular modellcsh:QH426-470Computational biologyBiology03 medical and health scienceschemistry.chemical_compoundGenetic variationmedicinegeneticsnatural variationGenetics (clinical)Genetic testingOriginal Researchmedicine.diagnostic_testmolecular modelingvariant of uncertain significanceGlucose transporterPrecision medicinePhenotypelcsh:Genetics030104 developmental biologychemistryMembrane proteinATSMolecular MedicineDNAFrontiers in Genetics
researchProduct

Monoclonal antibodies for the treatment of non-hematological tumors: a safety review

2018

Introduction: The introduction of monoclonal antibodies (moAbs) into clinical practice revolutionized the treatment strategies in several solid tumors. These agents differ from cytotoxic chemotherapy for their mechanism of action and toxicity. By targeting specific antigens present on healthy cells and modulating immune system activity, these biological drugs are able to generate a wide spectrum of peculiar adverse events that can negatively impact on patients' quality of life. Areas covered: In this review, the main side effects associated with the use of moAbs have been described to show their incidence and current management strategies, which may drive clinicians in their daily practice.…

0301 basic medicineOncologyAdverse eventPD-L1medicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentEGFRMonoclonal antibody03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Immune systemAntineoplastic Agents ImmunologicalInternal medicinePD-L1NeoplasmsPD-1medicineAnimalsHumansPharmacology (medical)Precision MedicineAdverse effectbiologybusiness.industrytarget therapymoAbsCancerAntibodies MonoclonalmoAbGeneral MedicineImmunotherapymedicine.diseaseVEGFSurvival Rate030104 developmental biologyCTLA-4HER-2030220 oncology & carcinogenesisAdverse eventsbiology.proteinQuality of LifeCTLA-4Adverse events; CTLA-4; EGFR; HER-2; immunotherapy; moAbs; PD-1; PD-L1; target therapy; VEGF; Pharmacology (medical)immunotherapybusiness
researchProduct

Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer

2020

BackgroundEGFR-positive Non-small Cell Lung Cancer (NSCLC) is a dynamic entity and tumor progression and resistance to tyrosine kinase inhibitors (TKIs) arise from the accumulation, over time and across different disease sites, of subclonal genetic mutations. For instance, the occurrence of EGFR T790M is associated with resistance to gefitinib, erlotinib, and afatinib, while EGFR C797S causes osimertinib to lose activity. Sensitive technologies as radiomics and liquid biopsy have great potential to monitor tumor heterogeneity since they are both minimally invasive, easy to perform, and can be repeated over patient’s follow-up, enabling the extraction of valuable information. Yet, to date, t…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyAfatinibEGFRprecision medicinelcsh:RC254-282cell free DNA; EGFR; liquid biopsy; non-small cell lung cancer; precision medicine; radiomics; tyrosine kinase inhibitors03 medical and health sciencesT790M0302 clinical medicineGefitinibInternal medicinetyrosine kinase inhibitorsmedicineOsimertinibLiquid biopsynon-small cell lung cancerOriginal ResearchReceiver operating characteristiccell free DNAliquid biopsybusiness.industrylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens030104 developmental biologyOncologyTumor progressionradiomics030220 oncology & carcinogenesisErlotinibbusinessmedicine.drug
researchProduct

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

2018

Current treatment options for advanced and recurrent head and neck squamous cell carcinoma (HNSCC) enclose radiation and chemo-radiation approaches with or without surgery. While platinum-based chemotherapy regimens currently represent the gold standard in terms of efficacy and are given in the vast majority of cases, new chemotherapy regimens, namely immunotherapy are emerging. However, the response rates and therapy resistance mechanisms for either chemo regimen are hard to predict and remain insufficiently understood. Broad variations of chemo and radiation resistance mechanisms are known to date. This study describes the development of a standardized, high-throughput in vitro assay to a…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyGeneral Chemical Engineeringmedicine.medical_treatmentCell Culture TechniquesGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences3D cell culture0302 clinical medicineInternal medicinemedicineCarcinomaHumansPrecision MedicineChemotherapyGeneral Immunology and MicrobiologySquamous Cell Carcinoma of Head and Neckbusiness.industryGeneral NeuroscienceHead and neck cancerImmunotherapymedicine.diseaseHead and neck squamous-cell carcinoma3. Good healthRegimen030104 developmental biologyHead and Neck Neoplasms030220 oncology & carcinogenesisCarcinoma Squamous CellPersonalized medicinebusinessJournal of Visualized Experiments
researchProduct

Spheroid-based 3D Cell Cultures Enable Personalized Therapy Testing and Drug Discovery in Head and Neck Cancer.

2017

Background/Aim: Chemo-radiation currently serves as first-line therapy of advanced and recurrent head and neck cancer, while new chemotherapy regimens are emerging. However, response rates to any treatment are difficult to predict and underlie broad variation. This study shows the development of a standardized, high-throughput in vitro assay to assess patients' individual response to therapy regimens as a future tool for personalized tumor therapy. Materials and Methods: Viability and proliferation analyses after chemo +/- radiation treatment of single spheroids (low adhesion plates/Hanging Drop (HD)) were generated from head and neck squamous cell carcinoma (HNSCC) cell lines and primary h…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyPathologyNecrosismedicine.medical_treatmentCell Culture TechniquesAntineoplastic Agents03 medical and health sciences3D cell culture0302 clinical medicineInternal medicineCell Line TumorSpheroids CellularDrug DiscoverymedicineTumor Cells CulturedHumansPrecision MedicineChemotherapybusiness.industryHead and neck cancerSpheroidGeneral MedicineChemoradiotherapymedicine.diseaseHead and neck squamous-cell carcinoma3. Good health030104 developmental biologyOncologyCell cultureHead and Neck Neoplasms030220 oncology & carcinogenesisPersonalized medicinemedicine.symptomDrug Screening Assays AntitumorbusinessAnticancer research
researchProduct

Next-Generation Sequencing Identifies Potential Actionable Targets in Paediatric Sarcomas

2021

Background: Bone and soft-tissue sarcomas represent 13% of all paediatric malignancies. International contributions to introduce next-generation sequencing (NGS) approaches into clinical application are currently developing. We present the results from the Precision Medicine program for children with sarcomas at a reference centre. Results: Samples of 70 paediatric sarcomas were processed for histopathological analysis, reverse transcriptase polymerase chain reaction (RT-PCR) and next-generation sequencing (NGS) with a consensus gene panel. Pathogenic alterations were reported and, if existing, targeted recommendations were translated to the clinic. Seventy paediatric patients with sarcomas…

0301 basic medicineOncologyCàncer en els infantsmedicine.medical_specialtyprecision medicinetargeted drugslcsh:MedicineMedicine (miscellaneous)Articlepaediatric sarcomasclinical translationDNA sequencinglaw.invention03 medical and health sciences0302 clinical medicinelawInternal medicineGene panelmedicineOssos MalaltiesPolymerase chain reactionPaediatric patientsBiological studiesbusiness.industrylcsh:RHistopathological analysisPrecision medicine030104 developmental biology030220 oncology & carcinogenesisCohortnext-generation sequencingbusinessJournal of Personalized Medicine
researchProduct

Molecular profile in Paraguayan colorectal cancer patients, towards to a precision medicine strategy

2019

[EN] Somatic mutation analysis and evaluation of microsatellite instability (MSI) have become mandatory for selecting personalized therapy strategies for advanced colorectal cancer and are not available as routine methods in Paraguay. The aims of this study were to analyze the molecular profile as well as the microsatellite status in a series of advanced colorectal patients from two public hospitals from Paraguay, to introduce these methodologies in the routine practice to guide the therapeutic decisions. Thirty-six patients diagnosed with advanced colorectal cancer from two referent public hospitals from Paraguay were recruited from May 2017 to February 2018. Sequenom Mass spectrometry, On…

0301 basic medicineOncologyMaleCancer Researchmutational profileColorectal cancerDNA Mutational AnalysisKaplan-Meier Estimate0302 clinical medicineOriginal ResearchCancer BiologyPrecision medicineHigh-Throughput Nucleotide SequencingMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisImmunohistochemistryOncology030220 oncology & carcinogenesisFemaleMicrosatellite InstabilityDisease SusceptibilityColorectal NeoplasmsAdultmedicine.medical_specialtyprecision medicinecolorectal cancerlcsh:RC254-28203 medical and health sciencesYoung AdultInternal medicinemedicineBiomarkers TumorHumansRadiology Nuclear Medicine and imagingAgedNeoplasm Stagingbusiness.industryMicrosatellite instabilityOncocartaPrecision medicinemedicine.diseaseColorectal cancerMutational profile030104 developmental biologyMutationMicrosatellite instabilityMolecular ProfileNeoplasm GradingbusinessLENGUAJES Y SISTEMAS INFORMATICOSMicrosatellite Repeats
researchProduct

BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients

2020

In the era of personalized medicine, BRAF mutational assessment is mandatory in advanced-stage melanoma and non-small cell lung cancer (NSCLC) patients. The identification of actionable mutations is crucial for the adequate management of these patients. To date various drugs have been implemented in clinical practice. Similarly, various methods may be adopted for the identification of BRAF mutations. Here, we briefly review the current literature on BRAF in melanoma and NSCLC, focusing attention in particular on the different methods and drugs adopted in these patients. In addition, an overview of the real-world practice in different Italian laboratories with high expertise in molecular pre…

0301 basic medicineOncologyProto-Oncogene Proteins B-rafmedicine.medical_specialtyPredictive molecular pathologyLung NeoplasmsGene mutationBRAF03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungMedicineHumansNon-Small-Cell LungVemurafenibLung cancerneoplasmsMelanomaTrametinibCobimetinibbusiness.industryBRAF; Lung cancer; Melanoma; Precision medicine; Predictive molecular pathology; Biomarkers; Humans; Mutation; Proto-Oncogene Proteins B-raf; Carcinoma Non-Small-Cell Lung; Lung Neoplasms; MelanomaCarcinomaPrecision medicineDabrafenibHematologyBiomarkerPrecision medicinemedicine.diseaseBRAF; Lung cancer; Melanoma; Precision medicine; Predictive molecular pathologyLung Neoplasm030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisMutationPersonalized medicineLung cancerbusinessBiomarkersmedicine.drugHuman
researchProduct

Liquid biopsy as surrogate for tissue for molecular profiling in pancreatic cancer: A meta-analysis towards precision medicine

2019

Liquid biopsy (LB) is a non-invasive approach representing a promising tool for new precision medicine strategies for cancer treatment. However, a comprehensive analysis of its reliability for pancreatic cancer (PC) is lacking. To this aim, we performed the first meta-analysis on this topic. We calculated the pooled sensitivity, specificity, positive (LR+) and negative (LR-) likelihood ratio, and diagnostic odds ratio (DOR). A summary receiver operating characteristic curve (SROC) and area under curve (AUC) were used to evaluate the overall accuracy. We finally assessed the concordance rate of all mutations detected by multi-genes panels. Fourteen eligible studies involving 369 patients wer…

0301 basic medicineOncologymedicine.medical_specialtyCancer ResearchConcordanceprecision medicinepancreatic cancerReviewlcsh:RC254-282Circulating tumor cells (CTC)03 medical and health sciences0302 clinical medicineInternal medicinePancreatic cancermedicineLiquid biopsycfDNALiquid biopsyReceiver operating characteristicliquid biopsybusiness.industryCfDNAPrecision medicinePancreatic cancerPrecision medicinemedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthCancer treatment030104 developmental biologyOncologycirculating tumor cells (CTC)030220 oncology & carcinogenesisMeta-analysisDiagnostic odds ratiobusinesscfDNA; circulating tumor cells (CTC); liquid biopsy; pancreatic cancer; precision medicine
researchProduct

Asynchronous and pathological windows of implantation: two causes of recurrent implantation failure

2018

STUDY QUESTION: Is endometrial recurrent implantation failure (RIF) only a matter of an asynchronous (displaced) window of implantation (WOI), or could it also be a pathological (disrupted) WOI? SUMMARY ANSWER: Our predictive results demonstrate that both displaced and disrupted WOIs exist and can present independently or together in the same RIF patient. WHAT IS KNOWN ALREADY: Since 2002, many gene expression signatures associated with endometrial receptivity and RIF have been described. Endometrial transcriptomics prediction has been applied to the human WOI in two previous studies. One study describes endometrial RIF to be the result of a temporal displacement of the WOI. The other indic…

0301 basic medicineOncologymedicine.medical_specialtyConcordanceprecision medicineBiologyEndometrial tissue03 medical and health sciencesEndometrium0302 clinical medicineImplantation failuretranscriptomic predictorsInternal medicinemedicinepolycyclic compoundsHumansendometrial asynchronyEmbryo Implantationendometrial pathologyendometriumPathologicalRetrospective Studiesrecurrent implantation failure030219 obstetrics & reproductive medicineGene Expression ProfilingRehabilitationConfoundingObstetrics and GynecologyRetrospective cohort studyEmbryo TransferPenetranceGene expression profilinggene expression signatures030104 developmental biologyReproductive Medicinemachine learning predictorswindow of implantation displacementFemaleTranscriptomeInfertility Femaletranscriptomic taxonomy
researchProduct